Last reviewed · How we verify

Celyad Oncology SA — Portfolio Competitive Intelligence Brief

Celyad Oncology SA pipeline: 1 marketed, 0 filed, 3 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 3 Phase 3 1 Phase 2 5 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Fludara Fludara marketed Carbonic anhydrase 5A, mitochondrial, DNA polymerase alpha catalytic subunit, Ribonucleoside-diphosphate reductase large subunit Oncology
ENDOXAN ENDOXAN phase 3 Alkylating agent DNA (non-specific alkylation) Oncology
Injection of C3BS-CQR-1 Injection of C3BS-CQR-1 phase 3 CAR-T cell therapy Oncology
Sham, no injection Sham, no injection phase 3

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Peking University People's Hospital · 2 shared drug classes
  2. Asahi Kasei Pharma Corporation · 1 shared drug class
  3. Beijing Yongtai Ruike Biotechnology Company Ltd · 1 shared drug class
  4. Astellas Pharma China, Inc. · 1 shared drug class
  5. Baxter · 1 shared drug class
  6. BeBetter Med Inc · 1 shared drug class
  7. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  8. Alberta Health services · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Celyad Oncology SA:

Cite this brief

Drug Landscape (2026). Celyad Oncology SA — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/celyad-oncology-sa. Accessed 2026-05-16.

Related